PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising three subtypes: PPAR, PPAR, and PPAR/. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR- reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR- causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR/- enhances fatty acids metabolism.
**PPAR Inhibitors & Modulators**

### (20S)-Protopanaxatriol

**Cat. No.**: HY-N0835

(20S)-Protopanaxatriol (g-PPT) is a metabolite of ginsenoside, protopanaxatriol (g-PPT), could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER).

**Bioactivity**: A metabolite of ginsenoside, protopanaxatriol (g-PPT), could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER).

**Purity**: 99.97%

**Clinical Data**: 10mM x 1mL in DMSO,

<table>
<thead>
<tr>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### Aleglitazar (R1439; RO0728804; R-1439; RO-0728804; R 1439; RO 0728)

**Cat. No.**: HY-14728

Aleglitazar (R1439; RO-0728804) is a new dual PPAR- agonist with IC50 of 2.8 nM/4.6 nM.

**Bioactivity**: A new dual PPAR- agonist with IC50 of 2.8 nM/4.6 nM.

**Purity**: 99%

**Clinical Data**: Phase 3

<table>
<thead>
<tr>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### Balaglitazone (DRF-2593; NN-2344; DRF259 3; NN2344; DRF 2593; NN 2344)

**Cat. No.**: HY-16086

Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-.

**Bioactivity**: Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-.

**Purity**: 98.13%

**Clinical Data**: Phase 3

<table>
<thead>
<tr>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>10mM x 1mL in DMSO,</td>
</tr>
</tbody>
</table>

### Bezafibrate

**Cat. No.**: HY-B0637

Bezafibrate (BM15075) is the first clinically tested dual and pan-PPAR co-agonism.

**Bioactivity**: Clinically tested dual and pan-PPAR co-agonism.

**Purity**: 99.67%

**Clinical Data**: 10mM x 1mL in DMSO,
**BMS-687453**
(BMS687453; BMS 687453)

**Cat. No.:** HY-10678

BMS-687453 is a potent and selective PPAR agonist, with an EC50 of 10 nM for human PPAR and 410-fold selectivity vs human PPAR in PPAR-GAL4 transactivation assays.

**Bioactivity:**

**Purity:** 99.7%

**Clinical Data:**

10mM x 1mL in DMSO,

**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**CDDO-Im**
(RTA-403; TP-235; CDDO-Imidazolide)

**Cat. No.:** HY-15725

CDDO-Im(RTA-403) is a novel synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo; PPAR agonist.

**Bioactivity:**

**Purity:** 98.2%

**Clinical Data:**

10mM x 1mL in DMSO,

**Size:** 5 mg, 10 mg
**Choline Fenofibrate**

(ABT-335; ABT 335; ABT335)

**Cat. No.:** HY-14739  
Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia.

**Bioactivity:** clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia.

**Purity:** 99.81%

**Clinical Data:** Phase 3, Phase 4

**Size:** 10mM x 1mL in DMSO, 10 mg, 100 mg

---

**Ciprofibrate**

(Win35833)

**Cat. No.:** HY-B0664  
Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

**Bioactivity:** proliferator-activated receptor agonist.

**Purity:** 99.6%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg
**Ciprofibrate D6**

Cat. No.: HY-B0664S  
Ciprofibrate D6 is deuterium labeled  
**Bioactivity:** Ciprofibrate, which is a peroxisome proliferator-activated receptor agonist.  
**Purity:** >98%  
**Clinical Data:**  
Size: 1 mg, 5 mg, 10 mg

**Clofibrate**

Cat. No.: HY-B0287  
Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.  
**Bioactivity:**  
**Purity:** 99.77%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO,  
Size: 1 g, 5 g

2 Tel: 609-228-6898Fax: 609-228-5909Email: sales@medchemexpress.com
Daidzein

(Isoflavone)

Cat. No.: HY-N0019

Bioactivity: Daidzein is a soy isoflavone, which acts as a PPAR activator.

Purity: 99.69%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 500 mg, 1 g, 5 g

DG172 (dihydrochloride)

(DG 172 dihydrochloride; DG-172 dihydrochloride)

Cat. No.: HY-19737A

Bioactivity: DG172 dihydrochloride is a novel PPAR- selective ligand showing high binding affinity (IC50 = 27 nM) and potent inverse agonistic properties.

Purity: 99.91%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 5 mg, 10 mg, 50 mg, 100 mg

Elafibranor

(GFT505; GFT-505; GFT 505)

Cat. No.: HY-16737

Bioactivity: Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor (PPAR)- and -, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

Purity: 99.31%

Clinical Data: Phase 3

Size: 10mM x 1mL in DMSO,

Size: 5 mg, 10 mg, 25 mg, 50 mg

Eupatilin

Cat. No.: HY-N0783

Bioactivity: Eupatilin, a flavone derived from Artemisia princepsPampanini, has various pharmacological activities, including antioxidant, anti-tumor, and anti-inflammatory capacities.

Purity: 98.31%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 5 mg, 10 mg, 25 mg, 50 mg
**Fenofibrate**

**Cat. No.:** HY-17356  
**Bioactivity:** Fenofibrate is a relatively potent inhibitor of **CYP2C19** ($IC_{50}=0.2$ M) and **CYP2B6** ($IC_{50}=0.7$ M). Fenofibrate is also a well-known PPAR agonist ($EC_{50}=30$ M).

**Purity:** 99.92%  
**Clinical Data:** Phase 3, Phase 4  
**Size:** 5 g, 10 g

**Fenofibric acid**

(FNF acid)

**Cat. No.:** HY-B0760  
**Bioactivity:** Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration.

**Purity:** 99.97%  
**Clinical Data:**  
10mM x 1mL in DMSO,  
**Size:** 1 g, 5 g
FH535

(FH 535; FH-535)

Cat. No.: HY-15721

Bioactivity: FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.

Purity: 99.9%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 10 mg, 50 mg

Gemfibrozil

(CI-719)

Cat. No.: HY-B0258

Bioactivity: Gemfibrozil (Lopid) is a compound used to lower lipid levels.

Purity: 99.46%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 100 mg, 500 mg
**GSK0660**

(GSK-0660; GSK 0660)

Cat. No.: HY-12377

GSK0660 is a specific antagonist of PPAR/γ, also has inverse agonist effects when used alone.

Bioactivity:

Purity: 99.27%

Clinical Data:

- 10mM x 1mL in DMSO,
- Size: 5 mg, 10 mg, 50 mg, 100 mg

**GSK3787**

(GSK 3787; GSK-3787)

Cat. No.: HY-15577

GSK3787 is as a selective and irreversible antagonist of PPAR with pIC50 of 6.6, with no measurable affinity for hPPAR or hPPAR.

Bioactivity:

Purity: 97.71%

Clinical Data:

- 10mM x 1mL in DMSO,
- Size: 10 mg, 50 mg

**GW501516**

(GW 1516; GSK-516; GW-501516)

Cat. No.: HY-10838

GW501516(GSK-516; GW1516) is a potent and highly selective PPAR/γ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPAR and hPPAR

Bioactivity:

Purity: 99.26%

Clinical Data:

**GW0742**

(GW610742; GW 0742; GW-0742; GW 610742; GW-610742)

Cat. No.: HY-13928

GW0742 (GW610742) is a potent and highly selective PPAR agonist.

Bioactivity:

Purity: 99.63%

Clinical Data:
GW1929

(GW 1929; GW-1929)

Cat. No.: HY-15655

GW1929 is a synthetic peroxisome proliferator-activated receptor-(PPAR) agonist with IC50 of 6.2 nM and 13 nM for human and mouse, respectively.

Bioactivity:

Purity: 99.68%

Clinical Data:

Size: 10mM x 1mL in DMSO,

5 mg, 10 mg, 50 mg, 100 mg

GW9662

(GW 9662; GW-9662)

Cat. No.: HY-16578

GW9662 is a selective PPAR antagonist for PPAR with IC50 of 3.3 nM, with ~10 and ~1000-fold functional selectivity in cells against PPAR and PPAR, respectively.

Bioactivity:

Purity: 99.93%

Clinical Data:

Size: 10mM x 1mL in DMSO,

5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Inolitazone

(Efatutazone; CS-7017; RS5444)

Cat. No.: HY-14792

Bioactivity:
Inolitazone (RS5444; CS-7017) is a novel high-affinity PPAR agonist, which activates PPAR with an EC50 about 1/50 that of rosiglitazone and has no effect on RIE cells that do not express PPAR.

Purity: >98%

Clinical Data:

Size: 5 mg

---

Inolitazone (dihydrochloride)

(Efatutazone; CS-7017; RS5444; CS 7017; RS 5444)

Cat. No.: HY-14792B

Bioactivity: Inolitazone dihydrochloride a novel high-affinity PPAR agonist that is dependent upon PPAR for its biological activity with IC50 of 0.8 nM for growth inhibition.

Purity: 97.34%

Clinical Data:

Size: 10mM x 1mL in DMSO, 5 mg
JW74

(JW-74; JW 74)

Cat. No.: HY-19739

Bioactivity:
JW74 is an efficient and specific inhibitor of the canonical Wnt signaling. JW74 shows a reduction of canonical Wnt signaling in the ST-Luc assay with IC50 values of 790 nM.

Purity: 99.93%

Clinical Data:

10mM x 1mL in DMSO,

Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-165041

(L 165041; L165041)

Cat. No.: HY-20019

Bioactivity: L-165041 is a cell permeable PPAR agonist which induces adipocyte differentiation in NIH-PPAR cells.

Purity: >98%

Clinical Data:

10mM x 1mL in DMSO,

Size: 5 mg, 10 mg, 50 mg, 100 mg
**Magnolol**

**Cat. No.:** HY-N0163  
**Bioactivity:** Magnolol, the main polyphenol compound of the bark of Magnolia officinalis, has a variety of pharmacological activities.  
**Purity:** 99.91%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO,  
Size: 10 mg, 50 mg, 100 mg

---

**Pemafibrate**

**Cat. No.:** HY-17618  
**Bioactivity:** Pemafibrate is a novel selective PPAR modulator (SPPARM) that has antihyperlipidaemic activity.  
**Purity:** 99.78%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO,  
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Pemafibrate (racemate)

Cat. No.: HY-17618A

Bioactivity: selective PPAR modulator (SPPARM).

Purity: >98%

Clinical Data:

Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Pioglitazone

(U 72107)

Cat. No.: HY-13956

Bioactivity: peroxisome proliferator-activated receptor gamma (PPAR) stimulator.

Purity: >98%

Clinical Data:

Size: 10 mg, 50 mg

Pioglitazone (hydrochloride)

(U 72107A; AD 4833)

Cat. No.: HY-14601

Bioactivity: potent and selective PPAR agonist with high affinity binding to the PPAR ligand-binding domain with EC$_{50}$ of 0.93 and 0.99 M for human and mouse PPAR, respectively.

Purity: 99.53%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 100 mg, 500 mg

Procyanidin B2

(Proanthocyanidin B2)

Cat. No.: HY-N0796

Bioactivity: exerts a potent and beneficial role in reducing granulosa cell apoptosis and inducing autophagy process, and exerts a variety of potent protective pharmacological effects on diabetic complications.

Purity: 99.36%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 1 mg, 5 mg, 10 mg, 25 mg
Retinoic acid (ATRA; Tretinoin; Vitamin A acid; all-trans-Retinoic acid)

Cat. No.: HY-14649

Bioactivity: Retinoic acid is a natural agonist of RAR/RXR nuclear receptors. Retinoic acid also bind to PPAR/, with $K_d$ of 17 nM.

Purity: 98.52%

Clinical Data:

Size: 10mM x 1mL in DMSO, 100 mg, 500 mg, 1 g, 5 g

Rosiglitazone

Cat. No.: HY-17386

Bioactivity: Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-) agonist, and is a blocker of TRPM2 and TRPM3 channels.

Purity: 99.46%

Clinical Data:

Size: 10mM x 1mL in DMSO, 50 mg, 200 mg
Rosiglitazone (maleate)

(BRL 49653C)

Cat. No.: HY-14600

Bioactivity: Rosiglitazone maleate (BRL-49653C) is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-(PPAR)

Purity: 99.66%

Clinical Data:

Size: 10mM x 1mL in DMSO,

Size: 100 mg, 500 mg

Saroglitazar

Cat. No.: HY-19937

Bioactivity: Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPAR and moderate PPAR activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.

Purity: 98.22%

Clinical Data:

Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Size: mg
**T0070907**

(T-0070907; T 0070907)

**Cat. No.: HY-13202**

**Bioactivity:**

T0070907 is a potent and selective PPAR antagonist with IC50 of 1 nM; displays > 800-fold selectivity for PPAR over PPAR and PPAR.

**Purity:** 99.98%

**Clinical Data:**

10mM x 1mL in DMSO,

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

**Troglitazone**

(CS-045)

**Cat. No.: HY-50935**

**Bioactivity:** Troglitazone is a PPAR agonist with anti-inflammatory and anti-tumor activity.

**Purity:** 96.55%

**Clinical Data:**

10mM x 1mL in DMSO,

**Size:** 10 mg, 50 mg

---

**Wy-14643**

(Pirinixinic acid)

**Cat. No.: HY-16995**

**Bioactivity:** Wy-14,643 (Pirinixinic acid) is a moderate agonist of PPAR and PPAR with IC50 of 36.5 M and 53.7 M, respectively.

**Purity:** 99.69%

**Clinical Data:**

10mM x 1mL in DMSO,

**Size:** 10 mg, 50 mg, 100 mg, 250 mg